Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: Role of the metabolic syndrome

High Blood Pressure and Cardiovascular Prevention

Volumn 18, Issue 4, 2011, Pages 195-201

  Guerra, Federico ^a   Mancinelli, Lucia ^a   Buglioni, Alessia ^a   Pierini, Valentina ^a   Rappelli, Alessandro ^a   Dess Fulgheri, Paolo ^a   Sarzani, Riccardo ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

hypertension; hypertensive organ damage; left ventricular hypertrophy; metabolic syndrome; microalbuminuria; obesity

Indexed keywords

ALBUMIN; CREATININE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CREATININE URINE LEVEL; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; PRIORITY JOURNAL; SMOKING;

ADULT; ALBUMINURIA; BLOOD PRESSURE; BODY MASS INDEX; CREATININE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT;

EID: 84856377941     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11593650-000000000-00000     Document Type: Article

References (30)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58
2. De Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol 2007; 27: 172-81
3. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-21
4. Leoncini G, Ratto E, Viazzi F, et al. Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 2008; 26: 427-32 (Pubitemid 351317250)
5. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the U.S. population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-36 (Pubitemid 36241019)
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9 (Pubitemid 32893993)
7. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16 (Pubitemid 35403784)
8. Reaven G. The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51: 931-8 (Pubitemid 40740871)
9. Kahn R, Buse J, Ferranini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2005; 28: 2289-304 (Pubitemid 41242486)
10. Schillaci G, Pirro M, Vaudo G, et al. Prognostic impact of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817-22 (Pubitemid 38622521)
11. Morisky DE, Ang A, Krousel-Wood MA, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10: 348-54
12. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87 (Pubitemid 46924065)
13. Grundy SM, Cleeman JI, Daniel SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-52 (Pubitemid 41532612)
14. Hallan S, Asberg A, Lindberg M, et al. Validation of the Modification of Diet in Renal Disease formula for estimating eGFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44: 84-93 (Pubitemid 38880931)
15. Bailey K, Grossardt B, Graves J. Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension 2008; 51: 841-7 (Pubitemid 351654693)
16. Sahn DJ, DeMaria A, Kisslo J, et al. The Committee on M-mode standardization of the American Society of Echocardiography. Circulation 1978; 58: 1072-3
17. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8 (Pubitemid 16119719)
18. De Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass; assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-62
19. Gerdts E, Okin PM, De Simone G, et al. Gender differences in left ventricular structure and function during antihypertensive treatment. Hypertens 2008; 51: 1109-14
20. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation 1987; 75: I26-33
21. Teicholz LE, Kreulen T, Herman MW, et al. Problems in echocardiographicangiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 7-11
22. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47 (Pubitemid 28213628)
23. Tsioufis C, Tsiachris D, Dimitriadis K, et al. Evidence for no global effect of metabolic syndrome per se on early hypertensive sequelae. J Hypertens 2008; 26: 773-9 (Pubitemid 351354926)
24. Schmieder RE. The role of non-hemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 2005; 20: 2610-2 (Pubitemid 41672256)
25. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008; 21: 500-8 (Pubitemid 351589672)
26. Cuspidi C, Meani S, Fusi V, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991-8 (Pubitemid 39336683)
27. Guerra F, Mancinelli L, Angelini L, et al. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS ONE 2011; 6: e16630
28. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80: 1270-7 (Pubitemid 41395958)
29. Perticone F, Maio R, Ruberto C, et al. Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension. Am J Kidney Dis 2008; 52: 74-84 (Pubitemid 351853261)
30. Leoncini G, Viazzi F, Conti N, et al. Renal and cardiac abnormalities in primary hypertension. J Hypertens 2009; 27: 1064-73